

AroCell Q4 - Positive development continues

Redeye provides an in-depth take on the Q4 report, and we are encouraged to see a consecutive quarter of positive EBITDA. Sales were in line with our estimates, and we appreciate the company emphasising more focus on geographical expansion, both in Europe and Asia.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

AroCell Q4 - Positive development continues